In contrast, Fadia et al.’s analysis of 81 PTC specimens revealed no correlation between PD-L1 levels and either tumor progression extent or high-risk clinical parameters (19), suggesting caution in using PD-L1 as a universal diagnostic marker. This evidence concerns the gene CD274 and neoplasm.